efineptakin alfa
- CAS No.
- 2026634-47-7
- Chemical Name:
- efineptakin alfa
- Synonyms
- efineptakin alfa
- CBNumber:
- CB013379375
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Efineptakin alfa 99.70% | CS-0635565 | 1mg | $704 |
| Efineptakin alfa 99.70% | CS-0635565 | 5mg | $1972 |
| Efineptakin alfa 99.70% | CS-0635565 | 10mg | $3142 |
| Efineptakin Alfa >98% | AA02EO9M | 1mg | $758 |
| Efineptakin Alfa >98% | AA02EO9M | 5mg | $2058 |
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 3K3WC6MT6P |
efineptakin alfa price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0635565 | Efineptakin alfa 99.70% | 2026634-47-7 | 1mg | $704 | 2026-06-04 | Buy |
| ChemScene | CS-0635565 | Efineptakin alfa 99.70% | 2026634-47-7 | 5mg | $1972 | 2026-06-04 | Buy |
| ChemScene | CS-0635565 | Efineptakin alfa 99.70% | 2026634-47-7 | 10mg | $3142 | 2026-06-04 | Buy |
| aablocks | AA02EO9M | Efineptakin Alfa >98% | 2026634-47-7 | 1mg | $758 | 2026-06-03 | Buy |
| aablocks | AA02EO9M | Efineptakin Alfa >98% | 2026634-47-7 | 5mg | $2058 | 2026-06-03 | Buy |
efineptakin alfa Chemical Properties,Uses,Production
Uses
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4+ and CD8+ cells in both human and mice. Efineptakin alfa can be used for glioblastoma research[1].
in vivo
Efineptakin alfa (10 mg/kg, IM, single) combined with SLC-3010 (1.8 mg/kg, IV, single) inhibits tumor growth in MC38-bearing mice[1].
Efineptakin alfa (10 mg/kg) mitigates RT-related lymphopenia, increases cytotoxic CD8 T lymphocytes systemically and in the tumor, and improves survival in orthotopic glioma-bearing mice[2].
| Animal Model: | C57BL/6 mice bearing intracranial tumors (GL261 or CT2A)[1] |
| Dosage: | 10 mg/kg |
| Administration: | On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion |
| Result: | Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFNγ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow. |
IC 50
IL7R
References
[1] Campian JL, et al. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. Clin Cancer Res. 2022 Mar 15;28(6):1229-1239. DOI:10.1158/1078-0432.CCR-21-0947
[2] Seungtae Baek, et al. rhIL-7-hyFc (efineptakin alfa; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex. 2022 AACR Abstract #4199.
efineptakin alfa Preparation Products And Raw materials
Raw materials
Preparation Products
efineptakin alfa Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 13636370518 | shyysw007@163.com | China | 89667 | 60 |
| Supplier | Advantage |
|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 60 |
